AnaptysBio Inc
NASDAQ:ANAB
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.85
40.33
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ANAB stock under the Base Case scenario is 19.13 USD. Compared to the current market price of 20.43 USD, AnaptysBio Inc is Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
AnaptysBio Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ANAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
AnaptysBio Inc
Balance Sheet Decomposition
AnaptysBio Inc
Current Assets | 448.7m |
Cash & Short-Term Investments | 430.1m |
Receivables | 12.2m |
Other Current Assets | 6.4m |
Non-Current Assets | 44.7m |
Long-Term Investments | 27.9m |
PP&E | 16.6m |
Other Non-Current Assets | 256k |
Current Liabilities | 43.9m |
Accounts Payable | 3.6m |
Accrued Liabilities | 40.3m |
Non-Current Liabilities | 365.2m |
Other Non-Current Liabilities | 365.2m |
Earnings Waterfall
AnaptysBio Inc
Revenue
|
57.2m
USD
|
Operating Expenses
|
-204.6m
USD
|
Operating Income
|
-147.4m
USD
|
Other Expenses
|
-18.2m
USD
|
Net Income
|
-165.7m
USD
|
Free Cash Flow Analysis
AnaptysBio Inc
USD | |
Free Cash Flow | USD |
ANAB Profitability Score
Profitability Due Diligence
AnaptysBio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
AnaptysBio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
ANAB Solvency Score
Solvency Due Diligence
AnaptysBio Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
AnaptysBio Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANAB Price Targets Summary
AnaptysBio Inc
According to Wall Street analysts, the average 1-year price target for ANAB is 54.77 USD with a low forecast of 23.23 USD and a high forecast of 94.5 USD.
Dividends
Current shareholder yield for ANAB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
Contact
IPO
Employees
Officers
The intrinsic value of one ANAB stock under the Base Case scenario is 19.13 USD.
Compared to the current market price of 20.43 USD, AnaptysBio Inc is Overvalued by 6%.